Wang Kexi, Zhong Jian, Su Danting, Leng Changsen, Fu Jianhua, Liu Qianwen
Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Department of Thoracic Surgery, Gaozhou People's Hospital, Maoming, China.
Ann Med. 2024 Dec;56(1):2433685. doi: 10.1080/07853890.2024.2433685. Epub 2024 Dec 2.
Due to its rarity, it is challenging to predict the survival of patients with synchronous multiple primary esophageal squamous carcinomas (SMPESCs). We aimed to construct nomograms to predict survival outcomes and help to make therapeutic strategy for patients with SMPESCs.
The clinical and survival data of 135 patients with SMPESCs were analyzed retrospectively. Univariate and multivariate Cox analyses were used to identify independent prognostic factors. Nomograms were constructed to predict 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS). In addition, we further evaluated the effect of postoperative adjuvant therapy on SMPESCs patients with lymph node metastasis.
In univariate and multivariate analyses of DFS and OS, age, site of the main lesion, lymph node metastasis, total number of lymph nodes dissected, lactate dehydrogenase level and lymphocyte-to-monocyte ratio were identified as independent prognostic factors. These characteristics were further included to establish nomograms. For the internal validation of the nomogram predictions of survival outcomes, the concordance indices were 0.752 and 0.756, respectively. Decision curve analysis also proved the efficacy of the nomograms. Furthermore, adjuvant therapy had a statistically significant benefit for OS but not DFS in patients with lymph node metastasis.
These nomograms could effectively predict the 1-year, 3-year and 5-year survival outcomes of patients with SMPESCs. Furthermore, adjuvant therapy has the potential to improve OS in patients with lymph node metastasis.
由于同步性多原发性食管鳞状细胞癌(SMPESCs)较为罕见,预测此类患者的生存情况具有挑战性。我们旨在构建列线图以预测生存结局,并帮助制定SMPESCs患者的治疗策略。
回顾性分析135例SMPESCs患者的临床和生存数据。采用单因素和多因素Cox分析确定独立预后因素。构建列线图以预测1年、3年和5年无病生存率(DFS)和总生存率(OS)。此外,我们进一步评估了术后辅助治疗对有淋巴结转移的SMPESCs患者的影响。
在DFS和OS的单因素及多因素分析中,年龄、主要病灶部位、淋巴结转移、清扫淋巴结总数、乳酸脱氢酶水平和淋巴细胞与单核细胞比值被确定为独立预后因素。将这些特征纳入以建立列线图。对于列线图生存结局预测的内部验证,一致性指数分别为0.752和0.756。决策曲线分析也证明了列线图的有效性。此外,辅助治疗对有淋巴结转移的患者的OS有统计学显著益处,但对DFS无显著益处。
这些列线图可有效预测SMPESCs患者的1年、3年和5年生存结局。此外,辅助治疗有可能改善有淋巴结转移患者的OS。